Microbiome

Solving development problems of probiotics and prebiotics

Microbiome

At Frontage, our scientific team has over a decade of experience in Microbiome Services to help you solve the development problems of therapeutics, probiotics and prebiotics.

We offer solutions for a wide range of indications including obesity, Type 2 diabetes, IBD, colorectal cancer, Immune diseases, bacterial and viral infections, and nervous system related diseases (gut-brain axis)

• Microbiome role in drug metabolism
• Understanding of microbiome biological processes
• Characterizations of major enzymatic pathways
• Heterogeneity of fecal microbiome between individuals and between species
• Standardize assays
• Alterations in microbiome metabolism between healthy and patient populations

HUMAN GUT MICROBIOME METABOLISM

Our scientific team can provide high-quality data to help you advance your microbiome project.

• Gut Metabolism
• Gut Biomarkers
• Gut Microbial Communities
• Metabolomics

ADVANCED STUDY CAPABILITIES

1. In Vitro anaerobic human gut microbiome metabolism studies in the following areas:

• Determination of Km and Vmax enzyme kinetic parameters in pooled human gut microbiome for multiple classes of xenobiotics with reference to metabolic probes for nitroreduction, deglycosylation, deacetylation, deglucuronidation, etc.
• Evaluation of microbiome-based formation of active metabolites
• Evaluation of microbiome-based metabolism with reference to colonic population diversity data by whole genome Shotgun sequence data
• Mechanistic study on metabolite formation by colonic genera / species
• Elucidation of colonic bacteria-derived metabolite structure by HR-LC-MS/MS

Microbiome Graphic 300x244 1 - Microbiome

2. In Vitro Human Microbiome Enzyme Kinetics in Patients and Healthy Subjects

• Determination of Km and Vmax enzyme kinetic parameters in pooled human gut microbiome for multiple classes of xenobiotics with reference to metabolic probes for nitroreduction, deglycosylation, deacetylation, deglucuronidation, etc.
• Evaluation of microbiome-based formation of active metabolites
• Evaluation of microbiome-based metabolism with reference to colonic population diversity data by whole genome Shotgun sequence data

3. Comprehensive LBA and LC-MS/MS Assay Panels of Human Gut Microbiome Biomarkers in Fecal Homogenate and Plasma

• Short-chain fatty acids
• Hepatic and bacterial bile acids
• Intestinal tight-junction biomarkers
• Intestinal inflammatory and immune-modulating biomarker panels
• Biomarkers assay panels by diseases and functions including: inflammatory bowel diseases, cardiovascular, bone, neurodegeneration, oncology and metabolic disorders including Type 2 diabetes

en_USEnglish